Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

PHERGain trial ID's early breast cancer cases that benefit from dual HER2...

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

Osimertinib after surgery significantly improves survival in resected EGFR...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Osimertinib after surgery significantly improves survival in resected EGFR-mutated NSCLC ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Ciltacabtagene autoleucel greatly reduces risk of disease progression in...

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA

ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to...

Dr Brian Van Tine - Washington University in St Louis, St Louis, USA

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma ( Dr Brian Van Tine - Washington University in St Louis, St Louis, USA )

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment ( Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA )

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )

Adding ribociclib to endocrine therapy shows an improvement in invasive disease...

Prof Dennis Slamon - UCLA, Los Angeles, USA

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )

Optimising cervical cancer care in Nigeria

Prof Don Dizon - Rhode Island Hospital, Rhode Island, USA

Optimising cervical cancer care in Nigeria ( Prof Don Dizon - Rhode Island Hospital, Rhode Island, USA )

More from ecancer